Advances in Treatment Options for Children and Adolescents with Type 2 Diabetes Mellitus




The incidence of type 2 diabetes mellitus (T2DM) in children and adolescents is dramatically increasing. Projections now estimate that over 1 million youths in the United States will have T2DM by the year 2050.

Earlier onset of T2DM leads to a longer lifetime exposure to hyperglycemia and consequently greater long-term complications. Until recently, children and adolescents were limited to only two regulatory-approved therapies for T2DM, metformin and insulin, which left few options for achieving glycemic control, preventing cardiovascular and other associated comorbidities, and maintaining an optimal quality of life.

This educational activity will provide an overview of the increasing prevalence of youth-onset T2DM, guideline recommendations for screening and management in the pediatric population, and an update on newly approved and emerging agents that provide alternative options to the use of metformin and insulin. Furthermore, clinicians will receive education on strategies to navigate barriers to lifestyle changes and adherence issues through effective communication and shared decision-making with the patient and caregivers.



Amy Sanghavi Shah, MD, MS
Associate Professor of Pediatrics
Director of the Pediatric Type 2 Diabetes Program
Cincinnati Children’s Hospital Medical Center
Cincinnati, Ohio


Charles Vega, MD
Clinical Professor of Family Medicine
Assistant Dean for Culture and Community Education
University of California, Irvine
Santa Ana, California


Release date: July 24, 2020
Expiration date: July 24, 2021
Estimated time to complete activity: 1.25 hour(s)



This educational initiative has been designed for pediatricians, endocrinologists, specialty nurse practitioners and physician assistants involved in the management of type 2 diabetes.


Upon completion of this educational activity, participants should be able to:

  • Describe the increasing prevalence of T2DM among children and adolescents, along with evidence-based screening and diagnostic recommendations to identify at-risk youth
  • Integrate guideline-directed strategies into routine management of children and adolescents with T2DM
  • Review efficacy and safety outcomes, mechanisms of action, and prescribing information on newly approved and emerging therapies for pediatric patients with T2DM
  • Apply effective communication strategies involving shared decision-making with the pediatric patient and family to achieve lifestyle changes and foster medication adherence

There are no fees for participating and receiving CME credit for this activity. During the period of July 24, 2020 to July 24, 2021, participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.




Integrity Continuing Education, Inc. is accredited with commendation by the Accreditation Council for Continuing Medical Education to provide continuing medical education (CME) for physicians.


Integrity Continuing Education, Inc. designates this enduring activity for a maximum of 1.25 AMA PRA Category 1 Credit(s). Physicians should claim only the credit commensurate with the extent of their participation in the activity.


For information about ACCME accreditation of this activity, please contact Integrity Continuing Education at (855) 835-4004 or


Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

Amy Sanghavi Shah, MD, MS
Has no real or apparent conflict of interest to report.

Charles Vega, MD
Has no real or apparent conflict of interest to report.

Rachel Brown, PharmD, hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.


This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. and Novo Nordisk, Inc. do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number, fax number, and…(continued)


Windows 98, 2000, XP, 2003, Vista, and 7
Internet Explorer 6/7
Firefox 2
Mozilla 1.7 or higher
Netscape 8.1 or higher
Flash Player 10

Mac OS X 10.3, 10.4
Safari 1.3 (Mac OS 10.3)
Safari 2.0 or higher (Mac OS 10.4)
Firefox 2
Flash Player 10
Use of Internet Explorer browser is not recommended.

Click here for more information on minimum system requirements.


The information provided in this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.


Provided by Integrity Continuing Education, Inc.


Supported by an educational grant from Novo Nordisk, Inc.


Continue to Pretest